|

NK cells Clinical Trials

4 actively recruiting trials across 3 locations

▲ +1 trial since August 2026

Pipeline

Phase 1: 3Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center3
  • Nationwide Children's Hospital1

Indications

  • Cancer4
  • NR3C11
  • Chimera Antigen Receptor (CAR)1
  • EGFRvIII1
  • IL13Ra1

Houston, Texas2 trials

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

MD Anderson Cancer Center

Phase 1
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

MD Anderson Cancer Center

Phase 1/2

Cleveland, Ohio1 trial

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Case Western Reserve University

Phase 1

Columbus, Ohio1 trial

Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

Nationwide Children's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.